SCHEMBL26699028

SCHEMBL26699028

Cc1oc2cnc(OCc3ccccc3F)cc2c1C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC26A4 O43511 7/20 0.55
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 1/20 0.44
BLM P54132 1/20 0.42
ATM Q13315 1/20 0.42
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
KDM5A P29375 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
ANO1 Q5XXA6 2/20 0.40
RARA P10276 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
GCK P35557 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30719910 1.00 SLC26A4 (0.55) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL30719895 0.89 PTGS2 (0.52) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL26699038 0.89 PTGS2 (0.52) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL30719888 0.85 CASP3 (0.56) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL26699026 0.85 CASP3 (0.56) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL30719750 0.83 SLC26A4 (0.39) SLC26A4KMT2AMEN1RARARARB
SCHEMBL30719905 0.83 SLC26A4 (0.48) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL26699024 0.83 SLC26A4 (0.48) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL24471003 0.82 SLC26A4 (0.81) SLC26A4KMT2AMEN1LMNAHTT
SCHEMBL30719728 0.82 SLC26A4 (0.38) SLC26A4KMT2AMEN1LMNARARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346605-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4532011-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
WO-2023227698-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023227698-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346605-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 SLC26A4 512/4885KMT2A 2570/4885MEN1 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.